trimetazidine / Generic mfg. - LARVOL DELTA

Lomerizine M6-An Important Urinary Metabolite in Anti-Doping Control Analysis for Correct Detection of Trimetazidine Abuse in Both Females and Males. (PubMed, Drug Test Anal) - "However, lomerizine M6 concentrations are not always higher than trimetazidine concentrations. Special care should be taken when interpreting trimetazidine concentrations at 1 ng/mL or below."

Journal • CNS Disorders • Migraine • Pain

Carfilzomib-induced sinus bradycardia: A case report and literature review. (PubMed, SAGE Open Med Case Rep) - "The condition was effectively managed following treatment with a combination of trimetazidine and salbutamol. To our knowledge, this is the first reported case of carfilzomib-associated sinus bradycardia, expanding the spectrum of proteasome inhibitors-related cardiotoxicity. This provides inspiration for suspected patients to stop using carfilzomib early and symptomatic treatment can effectively reduce mortality and improve prognosis."

Journal • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hematological Malignancies • Hypertension • Multiple Myeloma • Oncology

Study on the Mechanism of Trimetazidine Hydrochloride Alleviating Waterlogging Stress in Rapeseed (Brassica napus L.). (PubMed, Physiol Plant) - "Comprehensive analysis showed that TMZ could improve waterlogging tolerance of rapeseed by promoting antioxidant defense and osmotic adjustment, inhibiting fatty acid oxidation, accelerating glycolysis, and promoting photosynthesis efficiency. Various hormones, such as ethylene (ET), abscisic acid (ABA), jasmonic acid (JA), and brassinosteroid (BRs), could regulate this process through mutual synergy or antagonism."

Journal • CAT

Trimetazidine Attenuates Ulcerative Colitis-Linked Extrapyramidal Dysfunction by Mediated Dectin-1/LRRK2/α-Synuclein Autophagy Axis. (PubMed, Microsc Microanal) - "Molecular docking and dynamics confirmed TMZ binding to Dectin-1, LRRK2, and αSyn, through hydrophobic and hydrophilic interactions. These findings suggest a potential molecular basis for the observed associations between the Dectin-1/LRRK2/α-synuclein axis and UC-related motor dysfunction, warranting further experimental validation, establishing TMZ's therapeutic potential for managing colonic inflammation and associated neurological manifestations."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CLEC7A • IFNG • LAMP2 • LRRK2

Trimetazidine and allopurinol for the prevention of Contrast-associated acute kidney injury in elective percutaneous coronary intervention: a randomized controlled trial. (PubMed, Eur J Clin Pharmacol) - "The TMZ-allopurinol combination showed a favorable but non-significant trend toward reducing CA-AKI, while ACEF and Mehran scores demonstrated limited predictive value. Improved risk-stratification tools and larger studies in higher-risk patients are needed. SGLT2 and DPP-4 inhibitors showed smaller creatinine increases, suggesting possible nephroprotection, but this remains exploratory."

Journal • Acute Kidney Injury • Nephrology • Renal Disease

The myocardial ischemic cascade network and multi-target synergistic interventions: From molecular mechanisms to therapeutic innovations. (PubMed, Biochem Pharmacol) - "Cell death is targeted using ferroptosis inhibitors (e.g., Liproxstatin-1), NLRP3/caspase-1 blockers, and autophagy regulators (e.g., Astragaloside IV). Mitochondrial/metabolic therapies include mitochondrial-targeted drugs (e.g., CsA@PLGA-PEG-SS31), metabolic modulators (Trimetazidine), and neuroendocrine agents (ARNI, SGLT2 inhibitors)...Precision medicine integrates multi-omics and AI for risk stratification, while biomimetic nanocarriers enhance drug delivery. Future therapies should co-target the "energy-death-inflammation" network to advance myocardial ischemia treatment toward systemic repair and improved clinical outcomes."

Journal • Review • Cardiovascular • Gene Therapies • Inflammation • Metabolic Disorders • Myocardial Ischemia • Reperfusion Injury • ALDH2 • NLRP3 • SIRT3

Targeting ferroptosis by trimetazidine and probiotics to attenuate 5-fluorouracil-induced intestinal mucositis in mice. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The combination also provided additional improvement in intestinal structure (villus height, crypt depth, and enteritis score) compared with each monotherapy group. Either trimetazidine or probiotics alleviated 5-FU-induced intestinal mucositis and might be considered promising candidates for preventing CIM by anti-inflammatory, antioxidant, and mechanisms associated with modulation of ferroptosis-related pathways."

Journal • Preclinical • Gastrointestinal Disorder • Mucositis • Oncology • GPX4 • IL1B • SLC7A11

Kynurenine Pathway Metabolites as Mediators of Exercise-Induced Mood Enhancement, Fatigue Resistance, and Neuroprotection. (PubMed, Int J Mol Sci) - "Furthermore, pharmacological "exercise mimetics" and metabolic modulators, such as PPAR agonists, AMPK activators, NAD+ boosters, meldonium, trimetazidine, and adiponectin receptor agonists, may be promising adjuncts for patients with low exercise capacity or metabolic comorbidities...This perspective consolidates scattered mechanistic and clinical data and outlines a forward-looking therapeutic framework that links exercise and lifestyle, metabolism, and drug discovery. We highlight that re-consideration of our understanding of depression, as a whole-body disorder, should provide new opportunities for precision interventions."

Journal • Review • CNS Disorders • Depression • Fatigue • Immunology • Inflammation • Major Depressive Disorder • Mood Disorders • Psychiatry • FGF21 • IL6 • LEP

Effect of Long Term Trimetazidine Treatment on Final Myocardial Fibrosis for ST Eleviation Myocardial Infarction (clinicaltrials.gov) - P=N/A | N=194 | Completed | Sponsor: Chinese PLA General Hospital

New trial • Cardiovascular • Fibrosis • Immunology • Myocardial Infarction

Trimetazidine Ameliorates Progression of Diabetic Nephropathy by Reducing Serum Creatinine Level in Streptozotocin Induced Diabetic Rats. (PubMed, Mymensingh Med J) - "In TMZ treated group, whereas serum creatinine was significantly (p<0.01) lower when compared with STZ induced nephropathy groups of rats. It may be assumed from the present study that trimetazidine has cytoprotective as well as prevent renal damaged because of its special antioxidant effects, which can delay the onset, severity and progression of nephropathy induced by STZ in rats by reducing serum creatinine level."

Journal • Preclinical • Diabetic Nephropathy • Nephrology • Renal Disease

Mortality differences in coronary patients with breast cancer treated with trimetazidine dihydrochloride: potential therapeutic implications. (PubMed, Cardiooncology) - No abstract available

Journal • Breast Cancer • Oncology • Solid Tumor

Mechanistic insights into trimetazidine's protection against bladder ischemia-reperfusion injury via mirR-211/CHOP modulation and SIRT1/AMPK/PGC1α-mediated mitochondrial biogenesis. (PubMed, Toxicol Appl Pharmacol) - "TMZ exerts strong antioxidant, anti-inflammatory, anti-apoptotic, and cytoprotective effects in bladder I/R injury via modulation of oxidative stress, ER stress, mitochondrial pathways, and the mirR-211/CHOP axis. These findings suggest that TMZ may represent a promising therapeutic candidate for ischemia-associated bladder dysfunction, providing a mechanistic basis for future translational and clinical investigation."

Journal • Cardiovascular • Inflammation • Reperfusion Injury • Urology • AMPK • CASP3 • IL1B • SIRT1 • TNFA

Efficacy and Prognosis of Blinatumomab As a Bridge Therapy for Hematopoietic Stem Cell Transplantation for B-ALL (ASH 2024) - "MRD of the target genes was quantified using a multiparameter Flow cytometry, and the bridged Hematopoietic stem cell transplantation was performed after 7 days of 28 UG of Blinatumoma treatment, it uses dexamethasone to prevent CRS, Levetiracetam to prevent ICAN, and trimetazidine to nourish the myocardium.Methods : Forty-four patients (22 female, 22 male) , with a median age of 36.5(13-60 years) . With a median follow-up of 11 months, 41 patients had 1-year OS and PFS of 77.9% and 76.9% , respectively, and 10 MRD positive patients had 1-year OS and PFS of 66.4% and 65.6% , respectively, the 1-year OS and PFS of 31 MRD negative patients were 82.4% and 82% , respectively. Nine patients died after transplantation, including 9 from severe infection, 2 from GVHD and 3 from relapse.Result : Bridging transplantation after 7 days of continuous use of Blinatumoma has been shown to improve remission rates and long-term survival in patients with B-ALL, particularly in..."

Clinical • Bone Marrow Transplantation • Cardiovascular • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation

Intranasal Liposomal Trimetazidine Nanocarriers Modulate Neuroinflammation and Neurotransmission via the HMGB1/TLR4/NF-κB Pathway in an Experimental Epilepsy Model. (PubMed, Mol Neurobiol) - "These findings demonstrate the potential of intranasal delivery of NTMZ as a novel formulation for managing epilepsy through its improved bioavailability, reduced dose, sustained release, and potent neuroprotective properties. Simultaneously, pharmacological modulation of neuroinflammation and neurotransmitters were observed."

Journal • CNS Disorders • Cognitive Disorders • Epilepsy • Inflammation • Metabolic Disorders • HMGB1 • IL1B • IL6 • TLR4 • TNFA

Early combination therapy with trimetazidine rapidly improves symptoms and quality of life in patients recently diagnosed with stable angina: The COMBINE angina study. (PubMed, Int J Cardiol) - P | "The real-world COMBINE Angina study showed that early initiation of trimetazidine combination therapy can rapidly reduce the burden of stable angina in patients not promptly controlled by a first-line calcium channel blocker or β-blocker."

HEOR • Journal • Cardiovascular • Myocardial Ischemia

Comparative Hepatoprotective Effects of Dapagliflozin and Trimetazidine in Diabetic Rats with Doxorubicin-Induced Liver Injury. (PubMed, Biomedicines) - " Dapagliflozin and trimetazidine each attenuated diabetes- and doxorubicin-related hepatic injury through partly distinct mechanisms, with the combination providing additive but not consistently superior effects. These findings suggest a potential hepatoprotective role for both agents; however, the clinical implications remain uncertain and require confirmation in further mechanistic and translational studies."

Journal • Preclinical • Diabetes • Hepatology • Liver Failure • Metabolic Disorders • Oncology • CASP3 • NFKB1 • TGFB1 • TNFA

Trimetazidine Alleviates Heart Failure after Myocardial Infarction by Promoting PINK1/Parkin-mediated Mitophagy and Suppressing GPX4-Dependent Ferroptosis. (PubMed, Eur J Pharmacol) - "Molecular docking further validated TMZ's potential direct interaction with PINK1. In conclusion, these findings demonstrate that TMZ ameliorates post-MI heart failure by orchestrating mitochondrial quality control through promotion of mitophagy and suppression of GPX4-dependent ferroptosis, offering novel mechanistic insight into its therapeutic potential in the management of ischemic heart disease."

Journal • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Metabolic Disorders • Myocardial Infarction • GPX4 • MFN1 • SLC7A11

Targeting SIRT5 By Succinylating Hadha Synergizes with Venetoclax in Acute Myeloid Leukemia (ASH 2023) - "One of the mechanisms of action of the combination of venetoclax and azacitidine is to inhibit amino acid metabolism, leading to cell death...Moreover, the combination of trimetazidine (a specific inhibitor of HADHA) with venetoclax demonstrated a preferential reduction in cell proliferation and induction of apoptosis in AML cells... Targeting of SIRT5 in combination with venetoclax treatment results in synergistic cytotoxic effects in AML cells. We hypothesize that SIRT5 desuccinylase activity promotes FAO and reduces intracellular mitochondrial ROS levels by desuccinylating HADHA. Targeting SIRT5 inhibits fatty acid metabolism in AML cells, thereby enhancing the therapeutic effect of venetoclax."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Metabolic Disorders • Oncology • BCL2 • SIRT5

Cost-Effectiveness Model of Ranolazine for Treating Chronic Stable Angina Patients From Kingdom of Saudi Arabia Perspective (ISPOR-EU 2025) - "This insight, along with the importance of stratifying outcomes by angina severity and including revascularization impacts, guided the development of a 1-year decision tree model which compared ranolazine+sublingual nitro-glycerine (SNG) against placebo+SNG and trimetazidine+SNG. Trimetazidine was selected as the comparator due to its lower cost, high prevalence (approximately 95%) in Saudi Arabian second-line treatments, and superior safety profile compared to Ivabradine... Ranolazine is a cost-effective treatment compared to placebo and trimetazidine from KSA payor perspective. These findings are vital for optimizing healthcare resource allocation and ensuring patient access amidst rising costs."

Clinical • Cost effectiveness • HEOR • Cardiovascular

"Trimetazidine Protects against Doxorubicin-induced Chemobrain in Rats: Insights into Energy Imbalance and Neuroinflammation". (PubMed, Eur J Pharmacol) - "Notably, the 60 mg/kg dose of TMZ demonstrated superior efficacy. These findings provide a strong rationale for further clinical evaluation of TMZ-DOX combination regimens as a potential strategy to prevent DOX-associated cognitive impairment."

Journal • Preclinical • Alzheimer's Disease • Cardiomyopathy • Cardiovascular • CNS Disorders • Cognitive Disorders • Inflammation • CASP3 • TNFA

The crosstalk between mitochondrial dysfunction and fatty acid metabolism in heart failure: mechanisms and therapeutic strategies. (PubMed, Front Pharmacol) - "In addition, we provide an updated overview of therapeutic strategies, including pharmacological modulators such as SGLT2 inhibitors and trimetazidine, as well as traditional Chinese medicine formulas such as Qiliqiangxin and Qishen granules, which have shown preliminary benefits in clinical studies. Although the proposed vicious cycle remains a working hypothesis requiring further validation, understanding this interplay may help identify novel biomarkers, stratify patients by metabolic phenotype, and guide precision therapies for HF."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders

Endothelial Dysfunction in a Patient With Post-COVID-19 Syndrome and Mutation of the MTHFR Gene and Prothrombin II. (PubMed, Cureus) - "The patient initially received prophylactic anticoagulation with apixaban during hospitalization, which was discontinued after discharge. Long-term treatment included low-dose aspirin, folic acid, B-complex vitamins, bisoprolol, and trimetazidine for angina control...This case suggests that patients with platelet hyperreactivity, MTHFR (C677T), and prothrombin factor II (G20210A) mutations may be predisposed to developing ED and coronary microcirculatory impairment following SARS-CoV-2 infection in post-COVID-19 syndrome. We address the use of prophylactic anticoagulants in selected cases such as ours, which, although not specifically recommended by current guidelines (American Society of Hematology), may be considered after an individualized risk-benefit assessment."

Journal • Cardiovascular • Fatigue • Hematological Disorders • Infectious Disease • Inflammation • Metabolic Disorders • Novel Coronavirus Disease • Pain • Pulmonary Disease • Respiratory Diseases • MTHFR

Targeting the PHD2/HIF-1α/HO-1 pathway: A key role of trimetazidine in hypertensive nephropathy. (PubMed, Clin Exp Hypertens) - "These effects were further enhanced by PHD2 knockdown (TMZ + si-PHD2), but reversed by the inhibition of HO-1 or HIF-1α (TMZ + ZnPP, TMZ + KC7F2). TMZ improves HN in mice by modulating the PHD2/HIF-1α/HO-1 pathway."

Journal • Fibrosis • Immunology • Renal Disease • HIF1A • HMOX1

Ophthalmic antioxidant activity of a model antianginal drug using corneal hydrogel formulation: Effect of carboxymethyl starch on physicomechanical behaviour and release/permeation kinetics. (PubMed, Int J Biol Macromol) - "Flexible docking studies demonstrated a stronger binding interaction between TIZ and IL-1β (-5.4 kJ/mol) compared to diclofenac (-4.68 kJ/mol) and dexamethasone (-5.33 kJ/mol). Trimetazidine hydrogel could be used for controlled ophthalmic antioxidant activity after topical application. Presence of CMS improved physicomechanical performance."

Journal • Ophthalmology • IL1B

Reviving the Mitochondria: A Hopeful Horizon in Refractory Heart Failure. (PubMed, Cureus) - "Recent advances in mitochondrial-targeted therapies have opened new possibilities for treating HF at its energetic roots. This editorial explores the pathophysiological role of mitochondria in HF, reviews emerging therapeutic strategies aimed at restoring mitochondrial function, and outlines key challenges that must be addressed to translate these innovations into clinical practice."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders